Efficacy of pemetrexed for EGFR mutated lung carcinoma between L858R and Exon 19 deletion.

e19073 Background: A subgroup analysis of the Japanese patients in a LUX-LUNG 3 trial showed different progression-free survival (PFS) of cisplatin (CDDP) + pemetrexed (PEM) between an Exon 21 L858R (L858R) group (8.3 months) and Exon 19 deletion (19 del) group (3.1 months). PEM might have a different efficacy between L858R and 19 del. Methods: Consecutive patients with advanced/recurrent non-small cell lung cancer (NSCLC) harboring activating EGFR mutation were treated with platinum combined with PEM from our institute. The primary endpoint was to compare PFS of patients with L858R and that with 19 del in patients with EGFR mutated NSCLC. Results: A total of 32 patients treated between 2009 and 2013 were included. Median age was 67 years (range: 40 - 78). 13 patients (41%) had L858R and 19 patients (59%) had 19 del. Patients were treated with CDDP (n = 5) or carboplatin (n = 27) combined with PEM. Compared with 19 del, L858R included more female patients (64% versus 47%, p = 0.002); fewer patients treate...